Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study
ConclusionStandard dosing of enoxaparin in morbidly obese patients will most likely lead to supratherapeutic anti-Xa levels and thus further investigation is warranted to better determine appropriate dosing.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Bleeding | Drugs & Pharmacology | Eating Disorders & Weight Management | Lovenox | Obesity | Study | Thrombosis